Formycon Reports Initiation of P-I Trial for FYB202 (biosimilar- ustekinumab)
- The P-I study involves assessing of FYB202 vs Stelara in patients evaluating the PK- safety- and tolerability while their dosing has been started last week
- Bioeq GmbH to sponsor the trial and will take care of study design and clinical operation FYB202 is developed in a joint venture between Aristo Pharma GmbH and Formycon AG
- FYB202 is a mAb targeting cytokines interleukin-12 and interleukin-23 used for the treatment of several different serious inflammatory diseases- such as moderate to severe psoriasis including UC- Crohn’s disease and psoriatic arthritis
Click here to read full press release/ article | Ref: Formycon | Image: Behance
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com